Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental ...

The trade war between China and the US is entering the next round and reaching a new peak. The Middle Kingdom is restricting ...

U.S. drugmaker Pfizer on Tuesday raised its full-year profit forecast on strong demand for its heart disease drug, Vyndaqel, ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

These three dividend payers have an average yield of 4.5%. David Harrell: Hi, I’m David Harrell, editor of the Morningstar ...

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be announcing earnings results this Wednesday before the bell.

Resting-state EEG (RS-EEG) has emerged as a non-invasive, low-cost tool for Alzheimer’s disease (AD) diagnosis and ...